BIOA
Get informed when a big investor buys or sells
+ FollowOvervalued by 35.2% based on the discounted cash flow analysis.
| Market cap | $45.73 Billion |
|---|---|
| Enterprise Value | $45.55 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.24 |
| Beta | 0.93 |
| Outstanding Shares | 44,838,893 |
| P/E Ratio | -4.92 |
|---|---|
| PEG | -0.86 |
| Price to Sales | - |
| Price to Book Ratio | 1.74 |
| Enterprise Value to Revenue | 3488.17 |
| Enterprise Value to EBIT | -605.99 |
| Enterprise Value to Net Income | -646 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.04 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 682.58% |
|---|---|
| Total Calls | 510▼ 96.71% |
| Total Puts | -▼ 100.00% |
Holdings and activity of institutional investors.
| Ownership % | 11.30%▼ 84.12% |
|---|---|
| Total Invested | $117.68M▼ 80.36% |
| Investors Holding | 42▼ 106.00% |
No data
This particular fund is offered as a component within the ProShares Trust framework. Its central objective is to generate steady income, while concurrently prioritizing accessible funds and the safeguarding of investors' principal. A key...